Medtronic receives fda approval for smallest-diameter, lumenless defibrillation lead, the omniasecure™ lead and announces investigational clinical study results

Adding to the medtronic portfolio of catheter-based lead solutions, the novel omniasecure defibrillation lead allows for precise delivery and placement in the right ventricle heart rhythm 2025: late-breaking clinical study results evaluating the omniasecure lead for investigational use in the lbbap location show high defibrillation success  galway, ireland and san diego , april 25, 2025 /prnewswire/ -- medtronic plc (nyse: mdt), a global leader in healthcare technology, received u.s. food and drug administration (fda) approval for the omniasecure™ defibrillation lead for placement within the right ventricle. the lead, built on the highly reliable selectsecure™ model 3830 pacing lead and delivered via catheter, builds on the medtronic portfolio of lead solutions designed for precise delivery and placement.
MDT Ratings Summary
MDT Quant Ranking